Administered by qualified anesthesiologists or trained personnel using a calibrated vaporizer, ensuring precise concentration delivery via a face mask or endotracheal tube.

Sevoflurane is thought to produce general anesthesia by enhancing the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, inhibiting N-methyl-D-aspartate (NMDA) receptors, and modulating other ion channels such as potassium channels, leading to neuronal hyperpolarization and reduced excitability.

• •Known hypersensitivity to sevoflurane or other halogenated ethers.
• •Patients with a known or suspected susceptibility to malignant hyperthermia.
• •History of liver dysfunction, jaundice, or unexplained fever after previous sevoflurane or other halogenated anesthetic administration.

Store at controlled room temperature (20-25°C), protected from light. Keep container tightly closed when not in use.

Overdose leads to profound respiratory depression, cardiovascular depression (hypotension, bradycardia), and loss of reflexes. Management involves discontinuing sevoflurane, ensuring a patent airway, providing assisted or controlled ventilation with 100% oxygen, and maintaining cardiovascular function with fluids and vasopressors as needed.

Pregnancy Category B. Should be used during pregnancy only if clearly needed. Caution is advised when administered to a nursing mother, although minimal amounts are expected to be excreted in breast milk.